Article

Transient adverse events after REGN-CoV2 administration for mild COVID-19 patients and their potential predictive factors: a single center analysis

2021-11-29

Abstract excerpt

<h4>Background</h4> REGN-COV2, a monoclonal antibody cocktail drug against the SARS-COV-2 virus, has proven to be effective in preventing the development of severe COVID-19 and is increasingly being administered in outpatient and home settings. Adverse events such as fever and decreased oxygen saturation may occur after administration of REGN-COV2, and although these symptoms are generally mild and transient, pred...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2c3279c7-4a66-5dd7-bcbc-960dfefbb34a
DOI: 10.1101/2021.11.29.21266623

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Transient adverse events after REGN-CoV2 administration for mild COVID-19 patients and their potential predictive factors: a single center analysisDOI 10.1101/2021.11.29.21266623Read

Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity Read

Effect of Paxlovid Treatment During Acute Covid-19 on Long Covid Onset: An EHR-Based Target Trial Emulation from the N3C and RECOVER ConsortiaSemantic proximity Read

A 6-week time period may not be sufficient to identify potential adverse events following COVID-19 vaccinationSemantic proximity Read

Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study.Semantic proximity Read

[Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)].Semantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Clinical Characteristics of Mild/moderate COVID-19 Patients with a Prolonged Negative Conversion Time of SARS-CoV-2 Nucleic Acid DetectionSemantic proximity Read

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity Read

REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity Read

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from GreeceSemantic proximity Read

Real-world safety profile of Enfortumab Vedotin: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read

Generalized Rash in Severe Hospitalized COVID Patients: Correlation between Histological Examination, Drug Intake, Blood Interleukins Profileand Long-Term Follow-UpSemantic proximity Read